Carvacrol Silver Nanoparticles - An Effective Antibacterial Against Carbapenem-Resistant Acinetobacter Isolates Unaided and With Meropenem
DOI:
https://doi.org/10.36283/PJMD13-2/005Keywords:
Carvacrol, Acinetobacter, Carbapenems, Anti-Bacterial AgentsAbstract
Background: Acinetobacter species are a serious clinical challenge owing to their established resistance to carbapenems. This study aimed to explore Carvacrol silver nanoparticles' activity against carbapenem-resistant Acinetobacter and their interaction with meropenem to develop effectual treatment.
Methods: An in-vitro experimental study was conducted from February 2021 to January 2022. The minimum inhibitory concentration (MIC) of Carvacrol silver nanoparticles was checked using the broth macrodilution method. The results were further corroborated by performing the agar well diffusion method on 50 isolates of carbapenem-resistant Acinetobacter to observe the zone of inhibition (ZOI). The interaction of Carvacrol silver nanoparticles with meropenem (synergistic/additive/antagonistic) was assessed by checkerboard assay. SPSS vr24 was used. Kruskal-Wallis ANOVA with pair-wise comparison analysis was applied to compare different groups. p-value<0.05 was considered significant.
Results: The study showed that older males were mostly affected and the majority of the isolates were from the tracheal secretions and collected from the Medical ICU. MIC of Carvacrol silver nanoparticles was found to be 0.04-0.16mg/ml. On agar well diffusion, the ZOI of Carvacrol silver nanoparticles was in the range of 0-20mm compared to meropenem (0) and colistin (0-14mm) with a p-value of 0.00. Checkerboard assay revealed additive interaction between Carvacrol silver nanoparticles and meropenem as the Fractional inhibitory concentration was calculated to be 1.25.
Conclusion: Carvacrol silver nanoparticles have shown the potential ability to combat carbapenem-resistant Acinetobacter and may prove as an effective antibacterial agent in the future. Furthermore, the additive interaction of Carvacrol silver nanoparticles with meropenem points toward the possible revival of carbapenems against Acinetobacter.
References
Rebic V, Masic N, Teskeredzic S, Aljicevic M, Abduzaimovic A, Rebic D. The importance of Acinetobacter species in the hospital environment. medical archives. 2018;72(5):325. doi: 10.5455/medarh.2018.72.330-334
El-Sayed Ahmed MA, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019). Emerging microbes & infections. 2020;9(1):868-885. doi: 10.1080/22221751.2020.1754133
Iwu CD, Korsten L, Okoh AI. The incidence of antibiotic resistance within and beyond the agricultural ecosystem: A concern for public health. Microbiologyopen. 2020;9(9):e1035. doi.org/10.1002/mbo3.1035
Sharifi‐Rad M, Varoni EM, Iriti M, Martorell M, Setzer WN, del Mar Contreras M, Salehi B, Soltani‐Nejad A, Rajabi S, Tajbakhsh M, Sharifi‐Rad J. Carvacrol and human health: A comprehensive review. Phytotherapy Research. 2018;32(9):1675-1687. doi.org./10.1002/ptr.6103
Raei P, Pourlak T, Memar MY, Alizadeh N, Aghamali M, Zeinalzadeh E, Asgharzadeh M, Kafil HS. Thymol and carvacrol strongly inhibit biofilm formation and growth of carbapenemase-producing Gram negative bacilli. Cellular and Molecular Biology. 2017;63(5):108-112. doi.org/10.14715/cmb/2017.63.5.20
Trevisan DA, Silva AF, Negri M, Abreu Filho BA, Machinski Junior M, Patussi EV, Campanerut-Sá PA, Mikcha JM. Antibacterial and antibiofilm activity of carvacrol against Salmonella enterica serotype Typhimurium. Brazilian Journal of Pharmaceutical Sciences. 2018;54. doi.org/10.1590/s2175-97902018000117229
de Souza TA, Souza LR, Franchi LP. Silver nanoparticles: An integrated view of green synthesis methods, transformation in the environment, and toxicity. Ecotoxicology and environmental safety. 2019; 171:691-700. doi.org/10.1016/j.ecoenv.2018.12.095
Yin IX, Zhang J, Zhao IS, Mei ML, Li Q, Chu CH. The antibacterial mechanism of silver nanoparticles and its application in dentistry. International journal of nanomedicine. 2020; 15:2555. doi.org/10.2147/IJN.S246764
Ansari MA, Alzohairy MA. One-pot facile green synthesis of silver nanoparticles using seed extract of Phoenix dactylifera and their bactericidal potential against MRSA. Evidence-Based Complementary and Alternative Medicine. 2018;2018. doi.org/10.1155/2018/1860280
Liao S, Zhang Y, Pan X, Zhu F, Jiang C, Liu Q, Cheng Z, Dai G, Wu G, Wang L, Chen L. Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant Pseudomonas aeruginosa. International journal of nanomedicine. 2019; 14:1469. doi.org/10.2147/IJN.S1N1340
Chaloupka K, Malam Y, Seifalian AM. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends in biotechnology. 2010;28(11):580-588. doi.org/10.1016/j.tibtech.2010.07.006
Gliga AR, Skoglund S, Odnevall Wallinder I, Fadeel B, Karlsson HL. Size-dependent cytotoxicity of silver nanoparticles in human lung cells: the role of cellular uptake, agglomeration and Ag release. Particle and fibre toxicology. 2014; 11:1-7. doi.org/10.1186/1743-8977-11-11
Lal B, Vijayakumar S, Anandan S, Veeraraghavan B. Specimen Collection, Processing, Culture, and Biochemical Identification of Acinetobacter spp. InAcinetobacter baumannii 2019 (pp. 1-15). Humana Press, New York, NY. doi.org/10.1007/978-1-4939-9118-1_1
Ibrahim S, Ahmad Z, Manzoor MZ, Mujahid M, Faheem Z, Adnan A. Optimization for biogenic microbial synthesis of silver nanoparticles through response surface methodology, characterization, their antimicrobial, antioxidant, and catalytic potential. Scientific Reports. 2021;11(1):1-8. doi.org/10.1038/s41598-020-80805-0
Feroze N, Arshad B, Younas M, Afridi MI, Saqib S, Ayaz A. Fungal mediated synthesis of silver nanoparticles and evaluation of antibacterial activity. Microscopy Research and Technique. 2020;83(1):72-80. doi.org/10.1002/jemt.23390
Yang SK, Yusoff K, Mai CW, Lim WM, Yap WS, Lim SH, Lai KS. Additivity vs. synergism: Investigation of the additive interaction of cinnamon bark oil and meropenem in combinatory therapy. Molecules. 2017;22(11):1733. doi.org/10.3390/molecules22111733
Haque S, Ismail K, Khatoon A, Memon Z, Afridi FI, Shah R. Carvacrol Conjugated Zinc Oxide Nanoparticles as Prospective Agents against Clinically Isolated Carbapenem Resistant Acinetobacter Species. Med Forum 2022;33(9):33-37.
ul Ain Q, Naim A, Saeed A. Prevalence and resistance profile of clinical isolates of Acinetobacter species from Karachi, Pakistan. RADS Journal of Biological Research & Applied Sciences. 2019;10(1):6-13. doi.org/10.37962/jbas.v10i1.163.
Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R. The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017. Antimicrobial Resistance & Infection Control. 2020;9(1):1-10. doi.org/10.1186/s13756-020-00750-5.
Mukhtar SY, Hassan MM, Elkhidir IM. Prevalence of Acinetobacter spp. in Intensive Care Units of Selective Hospitals at Khartoum State, Sudan. American Journal of Microbiological Research. 2022;10(1):1-5. doi:10.12691/ajmr-10-1-1.
Zhao SY, Jiang DY, Xu PC, Zhang YK, Shi HF, Cao HL, Wu Q. An investigation of drug-resistant Acinetobacter baumannii infections in a comprehensive hospital of East China. Annals of clinical microbiology and antimicrobials. 2015;14(1):1-8. doi.org/10.1186/s12941-015-0066-4.
Rebic V, Masic N, Teskeredzic S, Aljicevic M, Abduzaimovic A, Rebic D. The importance of Acinetobacter species in the hospital environment. medical archives. 2018;72(5):325. doi: 10.5455/medarh.2018.72.330-334.
Gupta V, Ye G, Olesky M, Lawrence K, Murray J, Yu K. Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013–2017. BMC infectious diseases. 2019;19(1):1-9. Doi.org/10.1186/s12879-019-4387-3.
Begum S, Hasan F, Hussain S, Shah AA. Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pakistan journal of medical sciences. 2013;29(5):1253. doi: 10.12669/pjms.295.3695.
Devi N, Rani K, Kharb P, Prasad M. Herbal medicine for urinary tract infections with the blazing nanotechnology. Journal of Nanoscience and Nanotechnology. 2021;21(6):3495-3512. doi.org/10.1166/jnn.2021.19002.
Abootalebi SN, Mousavi SM, Hashemi SA, Shorafa E, Omidifar N, Gholami A. Antibacterial effects of green-synthesized silver nanoparticles using Ferula asafoetida against Acinetobacter baumannii isolated from the hospital environment and assessment of their cytotoxicity on the human cell lines. Journal of Nanomaterials. 2021;2021. doi.org/10.1155/2021/6676555.
Mohamedsalih PM, Sabir DK. Biosynthesis of silver nanoparticles using the aqueous extract of chamomile flower and their antibacterial activity against Acinetobacter spp. Health Biotechnology and Biopharma. 2020;3(4):48-62.
Sabir DK. Biosynthesized of Silver Nanoparticles from Myrtus communis Leaves and Investigates of their Antimicrobial Activities Against a Clinical Isolate of Acinetobacter baumannii. Acta Scientific Microbiology. 2022; 5:52-59. doi: 10.22034/HBB.2020.29.
Mickymaray S. One-step synthesis of silver nanoparticles using Saudi Arabian desert seasonal plant Sisymbrium irio and antibacterial activity against multidrug-resistant bacterial strains. Biomolecules. 2019;9(11):662. doi.org/10.3390/biom9110662.
Choi JS, Jung HC, Baek YJ, Kim BY, Lee MW, Kim HD, Kim SW. Antibacterial activity of green-synthesized silver nanoparticles using Areca catechu extract against antibiotic-resistant bacteria. Nanomaterials. 2021;11(1):205. doi.org/10.3390/nano11010205.
Khaled JM, Alharbi NS, Siddiqi MZ, Alobaidi AS, Nauman K, Alahmedi S, Almazyed AO, Almosallam MA, Al Jurayyan AN. A synergic action of colistin, imipenem, and silver nanoparticles against pandrug-resistant Acinetobacter baumannii isolated from patients. Journal of Infection and Public Health. 2021;14(11):1679-1685. doi.org/10.1016/j.jiph.2021.09.015
Panáček A, Smékalová M, Večeřová R, Bogdanová K, Röderová M, Kolář M, Kilianová M, Hradilová Š, Froning JP, Havrdová M, Prucek R. Silver nanoparticles strongly enhance and restore bactericidal activity of inactive antibiotics against multiresistant Enterobacteriaceae. Colloids and Surfaces B: Biointerfaces. 2016; 142:392-399. doi.org/10.1016/j.colsurfb.2016.03.007.
Tang S, Zheng J. Antibacterial activity of silver nanoparticles: structural effects. Advanced healthcare materials. 2018;7(13):1701503. doi.org/10.1002/adhm.201701503.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
